Decrease in the AgNOR number in dunning R3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone

Karoly Szepeshazi, Edib Korkut, Andrew V Schally

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The argyrophilic staining of the nucleolar organizer region (AgNOR) in cells of Dunning R3327 rat prostate tumors was studied and the effect of hormonal treatments on their appearance was analyzed. The nuclei of the control tumor cells contained 4.1 ± 0.17 AgNOR granules. Treatment of rats for 8 weeks with luteinizing hormone-releasing hormone (LH-RH) agonist (D-Trp-6-LH-RH) and antagonist SB-75 induced a marked inhibition of tumor growth and decreased significantly (P < 0.01) the number of Ag-NORs in the tumors to 2.89 ± 0.10 AgNOR granules/ cell in the group given the agonist and to 2.82 ± 0.10 after therapy with the highest dose of the antagonist. A reduced AgNOR number (3.14 ± 0.16) also was found after 3 days of treatment with SB-75 (P < 0.05), but the AgNORs returned to near control values 1 week after the short-term therapy, showing the reversibility of these changes. These results suggest that the AgNOR method, which was widely tested on human tumors in the past few years, can be a valuable technique in experimental tumor pathology and useful in the evaluation of the effects of various treatments.

Original languageEnglish
Pages (from-to)1273-1277
Number of pages5
JournalAmerican Journal of Pathology
Volume138
Issue number5
StatePublished - May 1 1991
Externally publishedYes

Fingerprint

Nucleolus Organizer Region
Gonadotropin-Releasing Hormone
Prostatic Neoplasms
Staining and Labeling
Neoplasms
Hormone Antagonists
Prostate
Pathology
Therapeutics
Growth

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Decrease in the AgNOR number in dunning R3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone. / Szepeshazi, Karoly; Korkut, Edib; Schally, Andrew V.

In: American Journal of Pathology, Vol. 138, No. 5, 01.05.1991, p. 1273-1277.

Research output: Contribution to journalArticle

@article{15fe7bb83f5543df81349a7d64ee745a,
title = "Decrease in the AgNOR number in dunning R3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone",
abstract = "The argyrophilic staining of the nucleolar organizer region (AgNOR) in cells of Dunning R3327 rat prostate tumors was studied and the effect of hormonal treatments on their appearance was analyzed. The nuclei of the control tumor cells contained 4.1 ± 0.17 AgNOR granules. Treatment of rats for 8 weeks with luteinizing hormone-releasing hormone (LH-RH) agonist (D-Trp-6-LH-RH) and antagonist SB-75 induced a marked inhibition of tumor growth and decreased significantly (P < 0.01) the number of Ag-NORs in the tumors to 2.89 ± 0.10 AgNOR granules/ cell in the group given the agonist and to 2.82 ± 0.10 after therapy with the highest dose of the antagonist. A reduced AgNOR number (3.14 ± 0.16) also was found after 3 days of treatment with SB-75 (P < 0.05), but the AgNORs returned to near control values 1 week after the short-term therapy, showing the reversibility of these changes. These results suggest that the AgNOR method, which was widely tested on human tumors in the past few years, can be a valuable technique in experimental tumor pathology and useful in the evaluation of the effects of various treatments.",
author = "Karoly Szepeshazi and Edib Korkut and Schally, {Andrew V}",
year = "1991",
month = "5",
day = "1",
language = "English",
volume = "138",
pages = "1273--1277",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Decrease in the AgNOR number in dunning R3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone

AU - Szepeshazi, Karoly

AU - Korkut, Edib

AU - Schally, Andrew V

PY - 1991/5/1

Y1 - 1991/5/1

N2 - The argyrophilic staining of the nucleolar organizer region (AgNOR) in cells of Dunning R3327 rat prostate tumors was studied and the effect of hormonal treatments on their appearance was analyzed. The nuclei of the control tumor cells contained 4.1 ± 0.17 AgNOR granules. Treatment of rats for 8 weeks with luteinizing hormone-releasing hormone (LH-RH) agonist (D-Trp-6-LH-RH) and antagonist SB-75 induced a marked inhibition of tumor growth and decreased significantly (P < 0.01) the number of Ag-NORs in the tumors to 2.89 ± 0.10 AgNOR granules/ cell in the group given the agonist and to 2.82 ± 0.10 after therapy with the highest dose of the antagonist. A reduced AgNOR number (3.14 ± 0.16) also was found after 3 days of treatment with SB-75 (P < 0.05), but the AgNORs returned to near control values 1 week after the short-term therapy, showing the reversibility of these changes. These results suggest that the AgNOR method, which was widely tested on human tumors in the past few years, can be a valuable technique in experimental tumor pathology and useful in the evaluation of the effects of various treatments.

AB - The argyrophilic staining of the nucleolar organizer region (AgNOR) in cells of Dunning R3327 rat prostate tumors was studied and the effect of hormonal treatments on their appearance was analyzed. The nuclei of the control tumor cells contained 4.1 ± 0.17 AgNOR granules. Treatment of rats for 8 weeks with luteinizing hormone-releasing hormone (LH-RH) agonist (D-Trp-6-LH-RH) and antagonist SB-75 induced a marked inhibition of tumor growth and decreased significantly (P < 0.01) the number of Ag-NORs in the tumors to 2.89 ± 0.10 AgNOR granules/ cell in the group given the agonist and to 2.82 ± 0.10 after therapy with the highest dose of the antagonist. A reduced AgNOR number (3.14 ± 0.16) also was found after 3 days of treatment with SB-75 (P < 0.05), but the AgNORs returned to near control values 1 week after the short-term therapy, showing the reversibility of these changes. These results suggest that the AgNOR method, which was widely tested on human tumors in the past few years, can be a valuable technique in experimental tumor pathology and useful in the evaluation of the effects of various treatments.

UR - http://www.scopus.com/inward/record.url?scp=0025762632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025762632&partnerID=8YFLogxK

M3 - Article

VL - 138

SP - 1273

EP - 1277

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 5

ER -